Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat versus hydroxyurea in high-risk JAK2V617F-positive polycythemia vera
NL-OMON60428Phase 3Recruiting
- Sponsor
- Italfarmaco
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in polycythemia vera (PV) comparing Givinostat with Hydroxyurea (2 arms). Primary endpoints: Response at Week 48 during core treatment phase and Long-term safety in extended treatment phase. Started Sep 2024; status: recruiting.
02
Drugs
givinostathydroxyurea
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NL-OMON60428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60428.